PAK Signaling Drives Acquired Drug Resistance to MAPK Inhibitors in BRAF-mutant Melanomas

Targeted BRAF inhibition (BRAFi) and combined BRAF and MEK inhibition (BRAFi+MEKi) therapies have significantly improved clinical outcomes in patients with metastatic melanoma. Unfortunately, the efficacy is beset by the acquisition of drug resistance(1–6). Here we investigated molecular mechanisms...

詳細記述

保存先:
書誌詳細
出版年:Nature
主要な著者: Lu, Hezhe, Liu, Shujing, Zhang, Gao, Wu, Bin, Zhu, Yueyao, Frederick, Dennie T., Hu, Yi, Zhong, Wenqun, Randell, Sergio, Sadek, Norah, Zhang, Wei, Chen, Gang, Cheng, Chaoran, Zeng, Jingwen, Wu, Lawrence W., Zhang, Jie, Liu, Xiaoming, Xu, Wei, Krepler, Clemens, Sproesser, Katrin, Xiao, Min, Miao, Benchun, Liu, Jianglan, Song, Claire D., Liu, Jephrey Y., Karakousis, Giorgos C., Schuchter, Lynn M., Lu, Yiling, Mills, Gordon, Cong, Yusheng, Chernoff, Jonathan, Guo, Jun, Boland, Genevieve M., Sullivan, Ryan J., Wei, Zhi, Field, Jeffrey, Amaravadi, Ravi K., Flaherty, Keith T., Herlyn, Meenhard, Xu, Xiaowei, Guo, Wei
フォーマット: Artigo
言語:Inglês
出版事項: 2017
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5891348/
https://ncbi.nlm.nih.gov/pubmed/28953887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature24040
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料